# Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

> **NCT02691182** · PHASE3 · TERMINATED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 491 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** SPN-810

## Key facts

- **NCT ID:** NCT02691182
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2021-05
- **Final completion:** 2021-05
- **Target enrollment:** 491 (ACTUAL)
- **Why stopped:** The program was shut down due to a lack of efficacy.
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02691182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02691182, "Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02691182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*